ArTara Therapeutics, Inc.(TARA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TARA ArTara Therapeutics, Inc.

休市中 02-13 16:00:00 EST

6.51

-0.02

-0.31%

盘后6.51

+0.000.00%

19:10 EST

最高6.82	最低6.46	成交量25.31万
今开6.55	昨收6.53	日振幅5.44%
总市值3.49亿	流通市值2.31亿	总股本5,359万
成交额167.87万	换手率0.71%	流通股本3,546万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TARA","market":"US","secType":"STK","nameCN":"ArTara Therapeutics, Inc.","latestPrice":6.51,"timestamp":1771016400000,"preClose":6.53,"halted":0,"volume":253059,"hourTrading":{"tag":"盘后","latestPrice":6.51,"preClose":6.51,"latestTime":"19:10 EST","volume":4097,"amount":26672.0721,"timestamp":1771027832247,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0030627871362940984,"floatShares":35462021,"shares":53587299,"eps":-1.38655,"marketStatus":"休市中","change":-0.02,"latestTime":"02-13 16:00:00 EST","open":6.55,"high":6.815,"low":6.46,"amount":1678667.382618,"amplitude":0.054364,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.38655,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"listingDate":1413950400000,"exchange":"NASDAQ","adjPreClose":6.53,"preHourTrading":{"tag":"盘前","latestPrice":6.61,"preClose":6.53,"latestTime":"09:05 EST","volume":602,"amount":3944.679648,"timestamp":1770991513718,"change":0.08,"changeRate":0.012251,"amplitude":0.026034},"postHourTrading":{"tag":"盘后","latestPrice":6.51,"preClose":6.51,"latestTime":"19:10 EST","volume":4097,"amount":26672.0721,"timestamp":1771027832247,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4848395462317376,"impliedVol":1.5229,"impliedVolPercentile":0.6375},"requestUrl":"/m/hq/s/TARA/wiki","defaultTab":"wiki","newsList":[{"id":"1106320216","title":"Protara Therapeutics启动静脉氯化胆碱三期关键性Thrive-3试验 首位长期肠外营养患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1106320216","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106320216?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:09","pubTimestamp":1767791396,"startTime":"0","endTime":"0","summary":"生物制药公司Protara Therapeutics宣布，其针对长期肠外营养患者开展的静脉氯化胆碱三期注册性Thrive-3临床试验已完成首位患者给药。该试验旨在评估药物对肠衰竭相关肝损伤的疗效，标志着公司核心管线推进的重要里程碑。基于胆碱缺乏与肝脂肪变性病理机制的紧密关联，此次试验设计包含多重疗效终点，包括肝脏脂肪含量影像学评估与生化指标改善等核心维度。随着首位患者给药完成，后续将加速推进多中心临床入组工作，为潜在的新药申请奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4139"],"gpt_icon":0},{"id":"1173704020","title":"ArTara Therapeutics, Inc.：Tara-002在BCG未治疗患者的12个月里显示出50%的完全反应率","url":"https://stock-news.laohu8.com/highlight/detail?id=1173704020","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173704020?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:20","pubTimestamp":1764768013,"startTime":"0","endTime":"0","summary":"ArTara Therapeutics, Inc.：Tara-002在BCG未治疗患者的12个月里显示出50%的完全反应率","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4139"],"gpt_icon":0},{"id":"1191729606","title":"Protara Therapeutics: Tara-002在BCG未治疗患者中的完全缓解率高达72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191729606","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191729606?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:15","pubTimestamp":1764767718,"startTime":"0","endTime":"0","summary":"Protara Therapeutics: Tara-002在BCG未治疗患者中的完全缓解率高达72%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"gpt_icon":0},{"id":"1160877626","title":"Protara Therapeutics公布积极的中期结果，显示在对患有淋巴畸形的儿童患者进行的Phase 2 Starborn-1试验中Tara-002的强烈反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1160877626","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160877626?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:01","pubTimestamp":1763557277,"startTime":"0","endTime":"0","summary":"Protara Therapeutics公布积极的中期结果，显示在对患有淋巴畸形的儿童患者进行的Phase 2 Starborn-1试验中Tara-002的强烈反应","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4139"],"gpt_icon":0},{"id":"1106440511","title":"ArTara Therapeutics, Inc.：88%的患者在接受一剂或两剂Tara-002治疗后取得临床成功","url":"https://stock-news.laohu8.com/highlight/detail?id=1106440511","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106440511?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:01","pubTimestamp":1763557273,"startTime":"0","endTime":"0","summary":"ArTara Therapeutics, Inc.：88%的患者在接受一剂或两剂Tara-002治疗后取得临床成功","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4139"],"gpt_icon":0},{"id":"1176687264","title":"ArTara Therapeutics, Inc.: Tara-002显示出良好的安全性和耐受性，无严重不良事件报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1176687264","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176687264?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:01","pubTimestamp":1763557271,"startTime":"0","endTime":"0","summary":"ArTara Therapeutics, Inc.: Tara-002显示出良好的安全性和耐受性，无严重不良事件报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4139"],"gpt_icon":0},{"id":"2518315746","title":"Protara Therapeutics(TARA.US)获LifeSci Capital首次覆盖，给予优于大市评级, 目标价22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518315746","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518315746?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:41","pubTimestamp":1741696881,"startTime":"0","endTime":"0","summary":"Protara Therapeutics(TARA.US)获LifeSci Capital首次覆盖，给予优于大市评级, 目标价22.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11204148668016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TARA"],"gpt_icon":0},{"id":"2518279833","title":"Protara Therapeutics, Inc.盘中异动 快速下跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279833","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518279833?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:31","pubTimestamp":1741617064,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时31分，Protara Therapeutics, Inc.股票出现异动，股价大幅下跌5.22%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3458.16%、731.26%、518.39%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223105abf312bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223105abf312bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TARA","BK4139"],"gpt_icon":0},{"id":"2517942764","title":"Protara Therapeutics, Inc.盘中异动 急速上涨5.36%报3.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517942764","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517942764?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:11","pubTimestamp":1741194675,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时11分，Protara Therapeutics, Inc.股票出现波动，股价急速拉升5.36%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.16%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Celularity Inc.涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为930.77%、302.46%、287.48%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306011116963b0023&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306011116963b0023&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TARA","LENZ"],"gpt_icon":0},{"id":"2517912526","title":"Protara Therapeutics(TARA.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.48美元，前值为-0.90美元，预期值为-0.56美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517912526","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517912526?lang=zh_cn&edition=full","pubTime":"2025-03-05 21:41","pubTimestamp":1741182093,"startTime":"0","endTime":"0","summary":"Protara Therapeutics(TARA.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.48美元，前值为-0.90美元，预期值为-0.56美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05214148547481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TARA","LENZ"],"gpt_icon":0},{"id":"1154035416","title":"Protara Therapeutics第四季度每股收益$(0.48)，优于预期的$(0.56)","url":"https://stock-news.laohu8.com/highlight/detail?id=1154035416","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154035416?lang=zh_cn&edition=full","pubTime":"2025-03-05 21:20","pubTimestamp":1741180844,"startTime":"0","endTime":"0","summary":"Protara Therapeutics 报告季度每股亏损$，优于分析师一致预期的$，提高了14.29%。相比去年同期每股亏损$，这是一个46.67%的增加。以上内容来自Benzinga Earnings专栏，原文如下：Protara $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 14.29 percent. This is a 46.67 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","LENZ"],"gpt_icon":0},{"id":"2516777546","title":"Protara Therapeutics, Inc.盘中异动 急速跳水5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516777546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516777546?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:36","pubTimestamp":1741099007,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时36分，Protara Therapeutics, Inc.股票出现波动，股价急速跳水5.52%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Exicure, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1087.57%、1073.51%、425.82%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Adma Biologics Inc，振幅分别为23.30%、22.25%、12.57%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223648abe7f184&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223648abe7f184&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TARA","LENZ","BK4139"],"gpt_icon":0},{"id":"2512192635","title":"Protara Therapeutics, Inc.盘中异动 临近收盘大幅下跌5.05%报3.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512192635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512192635?lang=zh_cn&edition=full","pubTime":"2025-02-19 04:51","pubTimestamp":1739911862,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日04时51分，Protara Therapeutics, Inc.股票出现异动，股价快速下跌5.05%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.72%。其相关个股中，Aditxt, Inc.、Allogene Therapeutics, Inc.、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为966.91%、222.60%、175.32%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219045102a24af961&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219045102a24af961&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TARA","BK4139","LENZ"],"gpt_icon":0},{"id":"2511359526","title":"Protara Therapeutics, Inc.盘中异动 早盘急速上涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511359526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511359526?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:41","pubTimestamp":1739457707,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时41分，Protara Therapeutics, Inc.股票出现异动，股价快速拉升5.18%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Pliant Therapeutics, Inc.涨幅较大，Tc Biopharm  Plc、Edesa Biotech, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1036.64%、998.14%、201.49%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Moleculin Biotech, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 ，振幅分别为69.33%、56.19%、32.86%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224147a244adb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224147a244adb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TARA","BK4139","LENZ"],"gpt_icon":0},{"id":"2509396203","title":"Protara Therapeutics, Inc.盘中异动 早盘股价大跌5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509396203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509396203?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:24","pubTimestamp":1738855490,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日23时24分，Protara Therapeutics, Inc.股票出现异动，股价大幅下挫5.41%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为5351.35%、1260.89%、131.39%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为103.10%、39.93%、36.09%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206232450abc4e10d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206232450abc4e10d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TARA","LENZ"],"gpt_icon":0},{"id":"2508147590","title":"Protara Therapeutics, Inc.盘中异动 早盘大幅跳水6.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508147590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508147590?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:02","pubTimestamp":1738594927,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时02分，Protara Therapeutics, Inc.股票出现波动，股价快速跳水6.50%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.72%。其相关个股中，Gh Research Plc、Invivyd, Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Cyclerion Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.、Invivyd, Inc.较为活跃，换手率分别为249.47%、82.04%、38.21%，振幅较大的相关个股有Invivyd, Inc.、Seastar Medical Holding Corporation、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为64.33%、33.48%、33.33%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032302089617013d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032302089617013d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TARA","BK4139","LENZ"],"gpt_icon":0},{"id":"2503884195","title":"Protara Therapeutics, Inc.盘中异动 早盘股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503884195","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503884195?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:34","pubTimestamp":1736778878,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时34分，Protara Therapeutics, Inc.股票出现波动，股价急速下跌5.00%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.99%。其相关个股中，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Kairos Pharma, Ltd.涨幅较大，Phio Pharmaceuticals Corp.、Salarius Pharmaceuticals, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为3139.26%、2040.50%、392.37%，振幅较大的相关个股有Salarius Pharmaceuticals, Inc.、Champions Oncology, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026，振幅分别为104.79%、102.87%、50.62%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132234389864d651&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501132234389864d651&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TARA","BK4139"],"gpt_icon":0},{"id":"2490488540","title":"Protara Therapeutics, Inc.盘中异动 早盘股价大跌5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490488540","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490488540?lang=zh_cn&edition=full","pubTime":"2024-12-10 22:31","pubTimestamp":1733841076,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日22时31分，Protara Therapeutics, Inc.股票出现异动，股价大幅下挫5.85%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Chimerix, Inc.、Uniqure N.V.、Klotho Neurosciences Inc C/Wts 21/06/2029 涨幅较大，Psyence Biomedical Ltd.、Processa Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为1643.12%、399.04%、84.92%，振幅较大的相关个股有Newamsterdam Pharma Company N.V.、Lava Therapeutics N.V.、Silexion Therapeutics Corp，振幅分别为10.21%、9.95%、9.70%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223116ab6cf51c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210223116ab6cf51c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TARA","LENZ"],"gpt_icon":0},{"id":"2489369742","title":"Protara Therapeutics, Inc.盘中异动 早盘大幅下跌7.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489369742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489369742?lang=zh_cn&edition=full","pubTime":"2024-12-06 22:31","pubTimestamp":1733495498,"startTime":"0","endTime":"0","summary":"北京时间2024年12月06日22时31分，Protara Therapeutics, Inc.股票出现异动，股价大幅下挫7.72%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。其相关个股中，Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Cardio Diagnostics Holdings Inc.、Hillevax, Inc.涨幅较大，Molecular Templates, Inc.、Psyence Biomedical Ltd.、Cardio Diagnostics Holdings Inc.较为活跃，换手率分别为21.61%、19.36%、11.17%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc.、Entero Therapeutics Inc.、Ensysce Biosciences, Inc.，振幅分别为10.19%、10.09%、9.80%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206223138a1d96ecc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206223138a1d96ecc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TARA"],"gpt_icon":0},{"id":"2488094611","title":"Protara Therapeutics, Inc.盘中异动 早盘股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488094611","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488094611?lang=zh_cn&edition=full","pubTime":"2024-12-03 22:31","pubTimestamp":1733236292,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日22时31分，Protara Therapeutics, Inc.股票出现异动，股价急速上涨5.09%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Janux Therapeutics, Inc.、Coherus Biosciences, Inc.、Vir Biotechnology, Inc.涨幅较大，Nls Pharmaceutics Ltd.、Purple Biotech Ltd、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为129.36%、56.56%、52.03%，振幅较大的相关个股有Coherus Biosciences, Inc.、Klotho Neurosciences, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为15.33%、12.00%、11.65%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203223132abf2f863&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203223132abf2f863&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TARA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protaratx.com","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":0.3178},{"period":"3month","weight":0.1815},{"period":"6month","weight":1.1485},{"period":"1year","weight":0.4897},{"period":"ytd","weight":0.2214}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Protara Therapeutics, Inc.最初于2006年3月24日在特拉华州注册成立。该公司是一家总部位于纽约市的临床阶段生物制药公司，致力于推进治疗癌症和罕见疾病的变革性疗法。该公司的产品组合包括两个利用TARA-002的开发项目，TARA-002是一种基于广泛免疫增强剂OK-432的研究性细胞疗法，该药物最初被日本厚生省授予上市许可，作为一种免疫增强型癌症治疗剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.112142},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.008006},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.047696},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.102878},{"month":5,"riseRate":0.272727,"avgChangeRate":0.052872},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.022412},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.047236},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.03111},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.021366},{"month":10,"riseRate":0.454545,"avgChangeRate":0.012653},{"month":11,"riseRate":0.833333,"avgChangeRate":0.1444},{"month":12,"riseRate":0.5,"avgChangeRate":0.040004}],"exchange":"NASDAQ","name":"ArTara Therapeutics, Inc.","nameEN":"ArTara Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ArTara Therapeutics, Inc.(TARA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ArTara Therapeutics, Inc.(TARA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ArTara Therapeutics, Inc.,TARA,ArTara Therapeutics, Inc.股票,ArTara Therapeutics, Inc.股票老虎,ArTara Therapeutics, Inc.股票老虎国际,ArTara Therapeutics, Inc.行情,ArTara Therapeutics, Inc.股票行情,ArTara Therapeutics, Inc.股价,ArTara Therapeutics, Inc.股市,ArTara Therapeutics, Inc.股票价格,ArTara Therapeutics, Inc.股票交易,ArTara Therapeutics, Inc.股票购买,ArTara Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ArTara Therapeutics, Inc.(TARA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ArTara Therapeutics, Inc.(TARA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}